Zhao S, Chen P, Wang X, Zheng Z, Hui R, Pang G
Quant Imaging Med Surg. 2024; 14(12):8387-8401.
PMID: 39698610
PMC: 11652052.
DOI: 10.21037/qims-24-428.
Na S, Kim M, Park Y, Kwon H, Shin H, Kim E
Breast Cancer. 2024; 31(4):705-716.
PMID: 38643429
PMC: 11194196.
DOI: 10.1007/s12282-024-01585-3.
Anderle N, Schafer-Ruoff F, Staebler A, Kersten N, Koch A, Onder C
J Exp Clin Cancer Res. 2023; 42(1):210.
PMID: 37596623
PMC: 10436441.
DOI: 10.1186/s13046-023-02782-2.
Xu W, Zheng B, Lu J, Liu S, Li H
BMC Med Imaging. 2023; 23(1):70.
PMID: 37264313
PMC: 10236691.
DOI: 10.1186/s12880-023-01022-5.
Rossi C, Fraticelli S, Fanizza M, Ferrari A, Ferraris E, Messina A
Breast Cancer Res Treat. 2023; 198(3):573-582.
PMID: 36802316
PMC: 10036406.
DOI: 10.1007/s10549-023-06872-9.
Biomarker Discordances and Alterations Observed in Breast Cancer Treated with Neoadjuvant Chemotherapy: Causes, Frequencies, and Clinical Significances.
Yilmaz C, Kocatepe Cavdar D
Curr Oncol. 2022; 29(12):9695-9710.
PMID: 36547175
PMC: 9776827.
DOI: 10.3390/curroncol29120761.
Noninvasive assessment of breast cancer molecular subtypes on multiparametric MRI using convolutional neural network with transfer learning.
Yin H, Bai L, Jia H, Lin G
Thorac Cancer. 2022; 13(22):3183-3191.
PMID: 36203226
PMC: 9663668.
DOI: 10.1111/1759-7714.14673.
How Reliable Are Gene Expression-Based and Immunohistochemical Biomarkers Assessed on a Core-Needle Biopsy? A Study of Paired Core-Needle Biopsies and Surgical Specimens in Early Breast Cancer.
Saghir H, Veerla S, Malmberg M, Ryden L, Ehinger A, Saal L
Cancers (Basel). 2022; 14(16).
PMID: 36010992
PMC: 9406531.
DOI: 10.3390/cancers14164000.
High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer.
Crozier J, Barone J, Whitworth P, Cheong A, Maganini R, Tamayo J
J Surg Oncol. 2021; 125(4):596-602.
PMID: 34964996
PMC: 9305900.
DOI: 10.1002/jso.26780.
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists.
Fusco N, Ragazzi M, Sajjadi E, Venetis K, Piciotti R, Morganti S
Histol Histopathol. 2021; 36(12):1235-1245.
PMID: 34585734
DOI: 10.14670/HH-18-376.
Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients.
Qi P, Yang Y, Bai Q, Xue T, Ren M, Yao Q
Breast Cancer Res Treat. 2021; 186(2):327-342.
PMID: 33439420
PMC: 7804587.
DOI: 10.1007/s10549-020-06075-6.
Non-Invasive Assessment of Breast Cancer Molecular Subtypes with Multiparametric Magnetic Resonance Imaging Radiomics.
Leithner D, Mayerhoefer M, Martinez D, Jochelson M, Morris E, Thakur S
J Clin Med. 2020; 9(6).
PMID: 32545851
PMC: 7356091.
DOI: 10.3390/jcm9061853.
Identifying breast cancer patients who require a double-check of preoperative core needle biopsy and postoperative surgical specimens to determine the molecular subtype of their tumor.
Park J, Kim H, Jung Y, Kim D, Kim J, Paik H
Ann Surg Treat Res. 2019; 97(5):223-229.
PMID: 31742206
PMC: 6848005.
DOI: 10.4174/astr.2019.97.5.223.
Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer.
Horvat J, Bernard-Davila B, Helbich T, Zhang M, Morris E, Thakur S
J Magn Reson Imaging. 2019; 50(3):836-846.
PMID: 30811717
PMC: 6767396.
DOI: 10.1002/jmri.26697.
Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry.
You K, Park S, Ryu J, Kim I, Lee S, Yu J
J Breast Cancer. 2017; 20(3):297-303.
PMID: 28970856
PMC: 5620445.
DOI: 10.4048/jbc.2017.20.3.297.
Concordance of DNA methylation profiles between breast core biopsy and surgical excision specimens containing ductal carcinoma in situ (DCIS).
Chen Y, Marotti J, Jenson E, Onega T, Johnson K, Christensen B
Exp Mol Pathol. 2017; 103(1):78-83.
PMID: 28711544
PMC: 5572810.
DOI: 10.1016/j.yexmp.2017.07.001.
A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.
Hadad S, Jordan L, Roy P, Purdie C, Iwamoto T, Pusztai L
BMC Cancer. 2016; 16(1):745.
PMID: 27658825
PMC: 5034430.
DOI: 10.1186/s12885-016-2788-x.
Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?.
Chatterjee S, Saha A, Arun I, Nayak S, Sinha S, Agrawal S
Breast Cancer (Dove Med Press). 2015; 7:381-8.
PMID: 26677343
PMC: 4677657.
DOI: 10.2147/BCTT.S94516.
Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.
Knutsvik G, Stefansson I, Aziz S, Arnes J, Eide J, Collett K
PLoS One. 2014; 9(11):e112121.
PMID: 25375149
PMC: 4223011.
DOI: 10.1371/journal.pone.0112121.
Accuracy of prognostic and predictive markers in core needle breast biopsies compared with excisional specimens.
Motamedolshariati M, Memar B, Aliakbaian M, Shakeri M, Samadi M, Jangjoo A
Breast Care (Basel). 2014; 9(2):107-10.
PMID: 24944553
PMC: 4038314.
DOI: 10.1159/000360787.